- Rating
- 1
- Confidence
- 4
- Informativeness
- 2
- Presentation
- 1
- Soundness
- 1
Read review
Paper summary
This paper introduces Pathology Harness, a framework for evidence-guided diagnostic finalization in computational pathology. The authors address the problem that a diagnostic prediction may be correct or plausible without being supported by sufficiently documented morphological evidence. The proposed framework introduces evidence contracts that specify the morphological observations and differential diagnostic requirements associated with a fixed diagnostic proposal. A Contract Auditor and a P3 Gate assess whether the collected evidence satisfies these requirements. When evidence is insufficient, the proposed DCE-Scout module selects additional regions and magnifications for further examination before making a finalization decision. Experiments are conducted primarily on BRACS and EBRAINS, comparing unconditional diagnostic release, evidence auditing without further observation, and evidence-guided follow-up. The results show that the proposed framework reduces the error rate among finalized diagnoses, from 55.6% to 18.9% on BRACS and from 28.1% to 11.0% on EBRAINS. However, these improvements come with substantially reduced diagnostic coverage.
Critical strengths
-
The paper addresses a meaningful problem in pathology agents by distinguishing diagnostic prediction from evidence-supported diagnostic finalization. A plausible prediction does not necessarily imply that the underlying morphological evidence has been adequately collected or documented. Introducing explicit evidence requirements and traceable decision records is a potentially valuable direction for improving the reliability and accountability of pathology agents.
-
The paper attempts to separate diagnostic prediction from finalization decisions by evaluating different policies using the same frozen diagnostic proposals and initial evidence records. This experimental design helps isolate the effect of evidence auditing and follow-up observation from changes in the underlying classifier. The reported risk–coverage analysis also provides useful information about the trade-off between reducing incorrect finalizations and withholding potentially correct diagnoses.
Critical weaknesses
1.The proposed framework is described at a rather abstract level, making it difficult to assess its technical novelty and reproducibility. Although the paper introduces several components, including evidence contracts, the Contract Auditor, P3 Gate, and DCE-Scout, their actual implementations are not sufficiently specified. For example, Appendix A.7 describes several possible implementations of the Contract Auditor without clearly identifying the one used in the experiments. Similarly, the construction of the actual evidence contracts and the scoring functions, optimization procedure, and hyperparameters used by DCE-Scout remain unclear. More importantly, the framework relies on these components to determine whether morphological evidence is sufficient, yet the validity of the evidence requirements and auditing decisions is not independently established. Consequently, it is difficult to determine whether the proposed system genuinely assesses diagnostic evidence or primarily enforces a set of predefined procedural rules. The presentation further complicates understanding. The main framework diagram (Figure 2) appears in the Related Work section, before the methodology, and the paper relies heavily on specialized terminology without providing a sufficiently concrete explanation of how the overall system operates.
2.The experimental evaluation is insufficient to establish the advantages of the proposed framework over existing pathology agents. Although the paper discusses several recent agent-based approaches, including CPathAgent, WSI-Agents, SlideSeek, and BEACON, these methods are not directly compared with Pathology Harness in terms of evidence acquisition, verification, and diagnostic finalization under comparable conditions. The reported comparisons mainly involve internal policy variants, unconditional release, and confidence-based selection. These baselines do not adequately establish the incremental contribution of the proposed framework relative to existing agentic approaches. Furthermore, the improvements in selective accuracy should be interpreted cautiously, as they are accompanied by a substantial reduction in diagnostic coverage. While the paper includes a confidence-based comparison at matched coverage on BRACS, the proposed method additionally acquires new observations, making the comparison unequal in terms of available information. Stronger controls, such as budget-matched alternative evidence acquisition strategies, are needed to determine whether DCE-Scout itself provides meaningful benefits. Overall, the current experiments demonstrate that selective finalization can reduce the error rate among released diagnoses, but they do not convincingly establish that the proposed framework offers a substantial advantage over existing evidence-seeking or verification-based approaches.
Questions for authors
1.Could the authors clarify the exact implementations used for the key components in the reported experiments? In particular, how were the evidence contracts constructed for BRACS and EBRAINS? What specific implementation was used for the Contract Auditor? How were the observability, differential relevance, diversity, and cost terms in DCE-Scout computed and combined? Providing the actual configurations and a complete execution example would be important for assessing the technical contribution and reproducibility of the method.
2.In Table 2, adding the P3 Gate to the Contract Auditor reduces the number of finalized BRACS cases from 152 to 64, eliminating 20 incorrect finalizations but also withholding 68 additional correct predictions. Could the authors explain which specific P3 checks are responsible for these decisions and why these checks are so strongly associated with diagnostic correctness? This clarification is important for understanding whether the reported improvement comes from meaningful evidence assessment or from restrictive release rules.
3.How is the clinical validity of the proposed evidence contracts and auditing decisions established? Were the morphological claims and evidence-sufficiency judgments independently evaluated by pathologists or against external annotations? In particular, can the authors provide an analysis of incorrect finalized cases to distinguish errors caused by inaccurate morphological observations, incomplete evidence requirements, and failures of the auditing procedure? Such evidence would be important for determining whether the framework genuinely improves evidence-grounded diagnostic reliability.
4.Could the authors provide comparisons with recent evidence-seeking or verification-based pathology agents, such as SlideSeek, WSI-Agents, or BEACON, under comparable evaluation settings? In particular, comparisons using the same initial diagnostic proposals and matched observation budgets would help establish whether Pathology Harness provides benefits beyond existing approaches. If direct comparisons are not feasible because of differences in task formulation, could the authors provide stronger budget-matched acquisition baselines and clarify the limitations of the current comparisons?